Below you will see the biographies for the candidates for this year's BIA Board election - to vote in the election click here.
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.
Lisa was President of AstraZeneca UK from 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior commercial and general management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.
Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to the US where she worked for a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.
Lisa joined the Board of the Association of the British Pharmaceutical Industry (ABPI) in 2012, chaired a number of UK industry committees and worked closely with Government and a wide range of industry stakeholders. She then became the first female President of the ABPI, a position from which she stepped down in 2018, and she was elected to the Board of the BIA in 2018.
Charlotte believes in equitable access to effective therapies. She is the CEO and Co-founder of Theolytics - a pre-clinical biotech company harnessing viruses to fight cancer - and has been a BIA Board Member since January 2019. This has included audit committee responsibilities, and the ongoing role of Vice Chair of the BIA's Skills, People and Talent Working Party.
Previously Co-founder and Director of New Medicine Partners, Charlotte has worked with organisations spanning three continents to support the early translation of novel life science technologies. She has taken leadership roles including Curator of the World Economic Forum Global Shapers network, Managing Director of HealthTech Women London, and HelloTomorrow’s London Chair for Healthcare and Medical Technologies.
Charlotte graduated as a University of Cambridge Bioscience Enterprise M.Phil Scholar and was a shortlisted finalist for Cambridge Entrepreneur of the Year. She was most recently named one of Forbes 30 Under 30, and In Vivo’s 30 Rising Leaders in Life Sciences.
Nicole is currently the General Manager for UK & Ireland Sanofi Genzyme, the specialty business unit of Sanofi. She has over 30 years of experience of working in the pharmaceutical and life sciences sector.
Nicole joined Sanofi Genzyme in 2016 as Head of MS for the UK & Ireland franchise, where she continued to build on the success and develop Sanofi’s MS franchise. She then moved on to lead the MS franchise for Europe for two years before returning to the UK & Ireland business in her new role, in May 2020.
Before joining Sanofi Genzyme, Nicole spent 2 years with Baxter, where she led the spin-out of the bioscience business to form Baxalta, where she was the UK Managing Director. Prior to this Nicole spent 26 years at Bayer (formally Schering Health Care) where she had roles ranging for sales representative for fertility care to UK Divisional Head, leading the radiological business for capital equipment, software and contrast media.
Nicole has a biochemistry degree and an MBA from Aston Business School.
Nicole has a passion for supporting others. She is a listening volunteer for Samaritans, an organization supporting people in crisis or suicidal, and mentors’ new volunteers. She has led teams of “non-sporty” people to complete triathlons and multi-day triathlons, and adventure races, with the strong conviction we can all do so much more than we imagine.
Oliver is seeking re-election to the BIA Board for a second term to continue supporting the BIA in securing the UK's position as a global hub in life sciences, by supporting company inception, scaling and value creation, built on the backbone of leading innovative research & development.
In 2013 Oliver founded Puridify, a biotech tools company, based at the Stevenage Bioscience Catalyst. In 2017, after leading the company through two rounds of venture capital funding, rapid growth, and preparing for product commercialisation, it was acquired GE Healthcare (now Cytiva). The disruptive purification technology platform was based on Oliver’s doctoral research at UCL in the department of Biochemical Engineering, where he remains as an honorary lecturer and regards industry-academia links as critical for the development of our industry.
Oliver has been fortunate to participate in the BIA’s manufacturing advisory committee for 8 years, seeing that community grow and provide a pivotal contribution to the BIA’s mission. While continuing to support MAC he has also been fortunate to Co-Chair the BIA Skill Working Party which has a crucial role to play in supporting the BIA through membership engagement & strategic initiative planning, to ensure we are able to find, train and support the people that will be required to deliver the growth vision for the UK’s life science sector.
Simon is CEO of Leaf Systems International Ltd and advisor to the Board of CamCon Medical Ltd. He served as Visiting Lecturer in Industrial Biotechnology, Vienna Medical and Technical University, Advisor at The Boston University School of Management, USA, and is a lecturer for the Cambridge University Masters in Biotechnology Enterprise (MBE) programme.
His international career in life sciences spans 40 years, beginning with two years at LMB Cambridge in the Clinical Oncology and Radiotherapeutics Unit, before moving into biotech in Cambridge with Coralab Research / Murex Diagnostics. Simon’s personal experience ranges from Research Scientist, technical sales, sales and marketing director, business division director and chief executive officer. He has been a founder and held senior management positions in biotech companies, including board director roles, since 1987. He has led the design, build and operation of GMP biologics manufacturing facilities in the UK, United States and Malaysia, including his role as Project Director for the design and build of the Cell and Gene Therapy Catapult Manufacturing Centre in Stevenage. Simon has been CEO of both private and public companies, and have led both the sale and acquisition of biotech companies.
He believes his experience would enable him to add significant value to the continued growth of the UK PLC life sciences industry and would welcome the opportunity to make that contribution through membership of the BIA Board.
Alison co-heads the international Life Sciences and Healthcare group at Taylor Wessing and has dedicated her career to helping life sciences companies to understand and utilise complex regulation so that their products can benefit patients in need.
In a career spanning over 20 years, Alison has helped hundreds of life sciences companies manage the range of legal challenges involved in commercialising medicinal products and medical devices, combining an encyclopaedic knowledge of the EU and UK life sciences regulatory environment with an analytical understanding of strategy and business in the life sciences sector. Her particular strength is at the point when products in development are ready to launch, where she is able to provide a rare combination of advice on regulation, compliance and commercialisation to help life science companies successfully launch their products. Alison also supports clients on outright acquisitions and licences, as well as navigating the nuances of structuring and negotiating arrangements with various commercial and health care partners within the complex framework of EU regulations, national laws and industry and deontological codes. Her expertise helps find the most options for companies seeking to develop and launch new products. Alison's experience, unique perspective and strong industry connections would all be valuable additions to the BIA and its members.
Dr Peter Finan
Pete has more than 25 years of experience in both drug discovery across the pharmaceutical industry and in building early-stage therapeutics companies. Prior to joining Epidarex, Pete was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK. In this role, he had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic.
Pete is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. In this capacity, he led target discovery, validation and early drug discovery programs across a wide range of therapeutic areas including oncology, neuroscience, regenerative medicine, autoimmunity and inflammation. The approaches used have been extensively published in Nature and Cell.
Pete’s experience from senior transatlantic industry roles to dealing with the day-to-day complexities of building venture-backed start-ups, ensures he is well qualified to join the BIA’s Board. He has an extensive global network of Pharma and Biotech contacts. Pete’s background in successfully funding innovative therapeutics start-ups is particularly relevant to the BIA’s goal of further establishing our industry as a global hub of drug discovery and development.
Dr Sally Ann Forsyth
Sally began her career with Unilever ultimately having lead responsibility for In-Licensing, Strategic Alliances and Open Innovation. She gained experience of creating supportive environments through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio, including the transformation of Harwell from a research campus into a leading science park. Her PhD is in molecular biology from the University of Cambridge and is a qualified management accountant (CGMA).
Sally is passionate about the translation of UK science into world leading innovations and with her combination of scientific and commercial expertise she feels that she could bring highly relevant experience to the BIA Board.
Her experience has been gained throughout the innovation supply chain through roles within academia, start-ups and major corporates. This has given her an understanding of the drivers and constraints of these organisations and how best to help them achieve their aims.
These areas of technology application are of particular relevance to the UK Innovation Strategy and government has been closely involved in this work. By building coalitions between academic, commercial and government organisations and she has been able to raise large amounts of funding. This has required a consultative and collaborative approach which she would bring to the Board if successful in her application.
Kath is Director of Life Sciences for Bruntwood SciTech. She is keen to join the BIA Board due to her interest and experience in growing life science businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a life science organisation. She can bring a deep understanding of the SME landscape in the UK, across the various life science subsectors, including support and finance needs and has indepth knowledge of regional life science assets, ecosystems, challenges and opportunities in UK regions, particularly in the North of the UK.
As Director of Life Sciences she is responsible for delivering the life science vision and growth strategy for Bruntwood SciTech, and developing sector specific innovation services and investment support to the life sciences businesses across our network. A scientist by training, she joined Bruntwood SciTech from the executive board of Innovate UK where I led the health and life science team and a £700m portfolio of infrastructure, Catapults, grant and loan investments. I am also Non-Executive Director of the Northern Health Science Alliance, the North of England’s health partnership, UKRI’s National Biofilms Innovation Centre, and Cheshire and Warrington Local Enterprise Partnership where I chair the Employer Skills and Education Board.
Emma is CEO at Weatherden, a drug development route-to-market design, strategy and execution consulting group. She has built multiple companies with breakthrough therapies; and is bringing to market deep tech solutions that will transform clinical trial design efficiency alongside property ventures that will pioneer a new hybrid network of biotech innovation clusters across Britain and Europe. Prior to Weatherden, Emma worked in the life sciences division at KPMG before moving into technical advisory, followed by three years at SV Health Investors working on biotech company creation in immunology and oncology. She advises early-stage life sciences and EIS funds, is passionate about encouraging broader participation in STEM and is active mentor to young entrepreneurs.
During her time at Weatherden, Emma has witnessed first-hand the many barriers to innovation, and is passionate about accelerating better drugs to patients, equality of access to clinical trials and ensuring the UK is best placed to maintain its position on the world stage and attract more investment from overseas.